ID: 7074516 (Ref.No. baf2dc4d)
Posted: January 28, 2021
Application Deadline: Open Until Filled
Postdoctoral Research Fellow --- in Cancer Immunology
Postdoctoral fellow positions are available in Dr. Li Lily Wang’s laboratory, in the department of Translational Hematology Oncology Research (THOR), https://www.lerner.ccf.org/thor/wang/ in the Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH. The Wang laboratory is engaging in cross-disciplinary studies by collaborating with basic and clinical researchers from LRI /CCF and the Case Comprehensive Cancer Center, affiliated with Case Western Reserve University.
Immune-checkpoint blockade (ICB) therapies have revolutionized the field of Cancer Immunotherapy. However, the low response rate in a majority of patients indicates the urgent need to identify and target additional checkpoint regulators. The Wang laboratory is among the first group to demonstrate that the immune-checkpoint protein “V domain Immunoglobulin Suppressor of T cell Activation” (VISTA) is a promising target for cancer immunotherapy (1 – 6). Current projects are focusing on elucidating the signaling mechanisms of VISTA in regulating the expansion, metabolism, and effector function of tumor-associated T cells, tumor-associated macrophages, and myeloid-derived suppressor cells.
We seek talented and committed candidates with a recent PhD with research training and experience in Biochemistry, Cell Biology, and Immunology to join our team. Interested candidates should submit CV, a statement of research interests in a cover letter, and three references to Dr. Li Lily Wang, firstname.lastname@example.org.
1.Wang L, RubinsteinR, Lines LJ, Wasiuk A, AhonenC, GuoYX, LuLF, Gondek D, WangY, Fava RA, Fiser A, Almo S and Noelle RJ. (2011) VISTA, a novel Ig-superfamily ligand that negatively regulates T cell responses, J Exp Med. 208(3):577-92. PMC3058578
2. Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L (2014) VISTA regulates the development of protective anti-tumor immunity. Cancer Research, 74:1933-1944. PMC4116689
3. Wang L, Le Mercier I, Putra J, Chen W, Liu J, Schenk AD, Nowak EC, Suriawinata AA, Li J, Noelle RJ. (2014) Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. PNAS. (41):14846-51 PMC4205642
4. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller H, Guleria I, Barth RJ, Huang YH, Wang L (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. PNAS. 112(21):6682-7, PMC4450438
5. Xu W, Táº¡ MH, Malarkannan S, Wang L(2018) Review: The structure, expression, and function of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular & Molecular Immunology. 2018 May 15(5):438-446 PMC6068175
6. Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta H, Miller H, Olson M, Rajasekaran K, Ernstoff M, Wang D, Malarkannan S, Wang L (2019) Immune checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunology Research PubMed PMID:31340983; NIHMSID:NIHMS1535762
By embracing and understanding the diversity EVERY ONE brings, Cleveland Clinic has created an inclusive culture that promotes innovation, growth, and new ideas. This has enhanced our ability to attract the best global talent to provide the best patient experience possible. Cleveland Clinic is pleased to be an equal employment/affirmative action employer: Women/Minorities/Veterans/Individuals with Disabilities. Smoke/drug free environment.